<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211847</url>
  </required_header>
  <id_info>
    <org_study_id>CT013</org_study_id>
    <nct_id>NCT01211847</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind DCCR-Fenofibrate Combination Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essentialis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Essentialis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Once a day oral administration with DCCR helps lower triglycerides&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The population will consist of Statin-naive and Statin-treated subjects, all without diabetes&#xD;
      mellitus, with fasting triglyceride levels in the range of ≥ 500 mg/dL and &lt; 1500 mg/dL.&#xD;
&#xD;
      Subjects will be randomly assigned to 1 of 2 treatment groups: DCCR and Placebo&#xD;
&#xD;
      Approximately 44 subjects will be enrolled in the study and stratified by Statin use at a 1:1&#xD;
      ratio in each treatment group,&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride-lowering efficacy of DCCR</measure>
    <time_frame>84 days</time_frame>
    <description>Fasting triglycerides (percent change from Baseline to Day 84)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in other lipid profiles with DCCR</measure>
    <time_frame>84 days</time_frame>
    <description>Apolipoprotein B (Apo B) (percent change from Baseline to Day 84) Fasting non-HDL cholesterol (percent change from Baseline to Day 84)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>DCCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCCR Treatment with 290 mg Diazoxide Choline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching DCCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide Choline Controlled-Release Tablet</intervention_name>
    <description>DCCR 290 mg once a day for 126 days</description>
    <arm_group_label>DCCR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching DCCR</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        Fasting triglycerides&#xD;
&#xD;
          -  Difference between Visit 3 (7 days prior to Baseline Visit) and Visit 4 (3 days prior&#xD;
             to Baseline Visit) ≤ 60% (compared to the higher value of Visit 3 or Visit 4)&#xD;
&#xD;
          -  Run-in Triglycerides* ≥ 500 mg/dL and &lt; 1500 mg/dL *Run-in Triglyceride is defined as&#xD;
             the average fasting triglycerides for Visit 3 (7 days prior to Baseline Visit) and&#xD;
             Visit 4 (3 days prior to Baseline Visit).&#xD;
&#xD;
        Statin use • Either Statin-naive&#xD;
&#xD;
          -  Must not be on statin at Screening and remaining as such during the Run-in/Washout&#xD;
             Period and throughout the study&#xD;
&#xD;
             • Or Statin-treated&#xD;
&#xD;
          -  Must be on Lipitor 20 mg initiated at the start of the Run-in/Washout Period and&#xD;
             continue throughout the study&#xD;
&#xD;
        Medication washout&#xD;
&#xD;
          -  All subjects must be willing to undergo washout of all other lipid-lowering&#xD;
             medications&#xD;
&#xD;
        Glycemic status&#xD;
&#xD;
          -  Fasting glucose &lt; 126 mg/dL at Screening Visit&#xD;
&#xD;
          -  HbA1c &lt; 6.5% at Screening Visit&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Medications: recent, current, anticipated&#xD;
&#xD;
          -  Administration of investigational drugs within 1 month prior to Screening Visit&#xD;
&#xD;
          -  Thyroid hormones or preparations within 1 month prior to Screening Visit (except in&#xD;
             subjects on stable dose of replacement therapy for at least 1 month)&#xD;
&#xD;
          -  Thiazide diuretics within 2 weeks prior to Screening Visit&#xD;
&#xD;
          -  Discontinuation of beta-blockers within 1 month prior to Screening Visit or planned&#xD;
             discontinuation of beta-blocker therapy&#xD;
&#xD;
          -  Anticipated requirement for use of prohibited concomitant medications&#xD;
&#xD;
        History of allergic reaction or significant intolerance to:&#xD;
&#xD;
          -  Diazoxide&#xD;
&#xD;
          -  Thiazides&#xD;
&#xD;
          -  Sulfonamides&#xD;
&#xD;
          -  Fenofibrate or fenofibric acid derivatives&#xD;
&#xD;
        Lifestyle changes&#xD;
&#xD;
        • Subjects intending to change exercise habits, quit smoking and/or quit alcohol use during&#xD;
        the entire study&#xD;
&#xD;
        Specific diagnoses, medical conditions and history&#xD;
&#xD;
          -  Known type I or III hyperlipidemia&#xD;
&#xD;
          -  Known type 1 DM&#xD;
&#xD;
          -  Current diagnosis of type 2 DM&#xD;
&#xD;
          -  Any other clinically significant endocrine, cardiovascular, pulmonary, neurological,&#xD;
             psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological&#xD;
             disease interfering with the assessments of the study medications, according to the&#xD;
             Investigator&#xD;
&#xD;
        Specific laboratory test results&#xD;
&#xD;
        • Any relevant biochemical abnormality interfering with the assessments of the study&#xD;
        medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Baron, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Essentialis, Inc.</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>triglycerides</keyword>
  <keyword>Apo B</keyword>
  <keyword>non-HDL</keyword>
  <keyword>statin</keyword>
  <keyword>fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazoxide</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

